<DOC>
	<DOCNO>NCT01297218</DOCNO>
	<brief_summary>The primary purpose study evaluate safety tolerability NEUROSTEM®-AD ( Human Umbilical Cord Blood Derived Mesenchymal Stem Cells ) ass maximum tolerate dose ( MTD ) . This study also investigate efficacy study drug patient dementia Alzheimer 's type .</brief_summary>
	<brief_title>The Safety The Efficacy Evaluation NEUROSTEM®-AD Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>Most treatment Alzheimer disease chemical drug design temporarily increase acetylcholine , base cholinergic hypothesis . These drug improve symptom able inhibit disease progression . New drug disease develop successful yet . Mesenchymal stem cell ( MSC ) capable differentiate various tissue . Due characteristic cell widely investigate tissue regeneration . In addition , paracrine effect MSC microenvironment recently report . MSC develop immunomodulation cell therapy product know cause immunological rejection allo- xeno-transplantation . Clinical study show umbilical cord blood-derived MSC immunologically stable toxic . This study evaluate safety tolerability NEUROSTEM®-AD ( Human Umbilical Cord Blood Derived Mesenchymal Stem Cells ) ass maximum tolerate dose ( MTD ) . This study also investigate efficacy study drug patient dementia Alzheimer 's type .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Korean men woman age 50 old Dementia determine DSMIV criterion Probable alzheimer 's disease determine NINCDSADRDA criterion KMMSE score range 10 24 Positive result PIBPET imaging ( SUV &gt; 1.5 , compare result cerebellum result frontal lobe ) Voluntarily participate subject sign consent form Subject psychological disease ( i.e . depression , schizophrenia , bipolar disorder , etc ) Subject dementia cause Alzheimer 's disease ( i.e . infection central nervous system , CreutzfeldJacob disease , severe head trauma , Pick 's disease , Huntington 's disease , Parkinson 's disease ) Subject vascular dementia determine clinical criterion DSM IV image criterion Erkinjuntii Subject severe white matter hyperintensities ( WMH ) ; Severe WMH define length deep white matter 25 mm long length periventricular capping/banding 10 mm longer . Subject stroke 3 month . Subject liver disease ( two time higher normal range ALT/AST ) Subject severe kidney failure ( 1.5mg/dL serum creatinine ) Pregnant woman lactate woman Hemoglobin &lt; 9.5g/dL men , &lt; 9.0 g/dL woman ; Total WBC count &lt; 3000/mm3 ; Total bilirubin ≥ 3 mg/dL Subject suspect active lung disease , base check Xray result Visit 1 Women childbearing age reject practice contraception Subject exclude subject selection process study A platelet count &lt; 150,000/mm3 ; PT ≥ 1.5 ; INR aPTT ≥ 1.5 X control Subject cancer History alcohol drug abuse Subject undergo MRI , CT , PET screen Subject undergo anesthesia stereotactic brain injection Subject determine inappropriate investigator</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Alzheimer , Mesenchymal Stem Cells , Umbilical Cord Blood</keyword>
</DOC>